FDA Accepts Gilead's NDA for Idelalisib Against Indolent Lymphomas
According to Gilead Sciences, a biopharmaceutical company in the business of innovative therapeutics based in the San Francisco Bay area, the US Food and Drug Administration has accepted for review the company's New Drug Application (NDA) for idelalisib.
Idelalisib is an investigational, highly selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta. PI3K delta signaling is critical for the activation, proliferation, survival and trafficking of B lymphocytes and is hyperactive in many B-cell malignancies.
The current NDA is for the treatment of refractory indolent non-Hodgkin's lymphoma (iNHL).
Gilead submitted the NDA on Sept. 11, 2013. Since the FDA granted standard review, it has set a target review date under the Prescription Drug User Fee Act (PDUFA) of Sept. 11, 2014.
Gilead's NDA for iNHL is supported by a single arm Phase II study evaluating idelalisib in patients with iNHL that is considered refractory to rituximab and to alkylating-agent-containing chemotherapy.
The FDA previously granted idelalisib a Breakthrough Therapy designation for relapsed chronic lymphocytic leukemia (CLL), and Gilead previously submitted an NDA for the same drug back in December of 2013 for CLL treatment.
Source: Gilead
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
